The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
Notice for olaratumab (rmc) (Eli Lilly Australia Pty Ltd)
Active ingredients
olaratumab (rmc)
Sponsor
Date of review outcome
Lapse date
Type
Orphan drug
Dosage form(s)
Injection, intravenous infusion
Indication
For the treatment of soft tissue sarcoma